neonatal care News
-
Neonatal Incubator Developed By MOm And Eg Technology Achieves First Clinical Use In The UK
Created by mOm Founder & CEO, James Roberts, and developed by mOm & the engineering team at eg technology, this innovative, lightweight incubator helped to sustain a premature baby’s life at St Peter’s Hospital, Chertsey. The mOm incubator was originally conceived to save the lives of premature babies in challenging, low/middle-income settings; as well as provide more options ...
-
New study reports activated B. infantis EVC001 feeding substantially reduces enteric inflammation, diaper rash and antibiotic use in preterm infants
Researchers publishing in the peer-review journal Frontiers in Pediatrics report that pre-term infants fed Bifidobacterium longum subsp. infantis (activated B. infantis EVC001) experienced significantly lower level of intestinal inflammation, 62% less diaper rash, and required 62% fewer antibiotics– all of which are critical health indicators in neonatal care. The study, Impact of ...
-
Study Results Are In On A Potential Non-Invasive Treatment For Rds
For little lungs everywhere, the families that love them, and the neonatologists who care for them, there’s news coming out of ONY Biotech, a family-focused neonatology pharmaceutical company. Today, ONY Biotech announced the results of a clinical trial on its aerosolized surfactant for newborns with respiratory distress syndrome (RDS), a disorder caused by lack of surfactant that can ...
By ONY Biotech
-
Microbial Outbreak Results in Deaths at Neonatal Intensive Care Unit
Cinnaminson, NJ, August 8th, 2012 The Health Minister of the Bahamas recently ordered an investigation into an outbreak of a microbial pathogen at a neonatal intensive care unit. The outbreak, caused by a type of bacteria known as Acinetobacter baumannii, is believed to have sickened eight infants and caused two of the infants to die. Outbreaks of Acinetobacter baumannii in healthcare ...
-
Recent microbiome study finds that Intus Bio’s products differentiate closely related gut bacteria in premature infants
Products from Intus Biosciences demonstrated high-resolution tracking of specific bacterial strains in a recent microbiome study, the results of which are being applied to better understand how pathogens and commensals become established in premature infants in neonatal intensive care units (NICU), with the goal of improving outcomes for premature infants. Intus Biosciences is a microbiome ...
-
Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that the Food and Drug Administration (FDA) has granted it's lead compound, ENA-001, rare pediatric disease designation for the treatment of Apnea of Prematurity. Enalare is planning to develop this unique agnostic ...
-
Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you